Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04422366 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Study site revisedv3
  3. Enrollment target: 9600 to 8000v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .
Trial Details
NCT Number NCT04422366
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1, CIN2, CIN3, VaIN1, VaIN2 +6 more
Related terms Condylomata Acuminata, Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms
Enrollment 8,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov